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Steven A. Pergam,1,2,3 Hu Xie,2 Ravinder Sandhu,2 Margaret Pollack,1,3 Jeremy Smith,4
Terry Stevens-Ayers,1 Valeria Ilieva,1 Louise E. Kimball,1 Meei-Li Huang,5
Tracy S. Hayes,5 Lawrence Corey,1,2,3,5 Michael J. Boeckh1,2,3Cytomegalovirus (CMV) transmission via stem cells or marrow in CMV donor seropositive/recipient sero-
negative (D1/R2) hematopoietic cell transplantation (HCT) is surprisingly inefficient, and factors associated
with transmission in these high-risk HCTrecipients are unknown. In a retrospective cohort of D1/R2HCT
recipients, cumulative incidence curve estimates were used to determine posttransplantation rates of CMV
andmultivariable Cox proportional models to assess risk factors associated with transmission. A total of 447
patients from 1995 to 2007were eligible for enrollment. Overall, 85 of 447 (19.0%) acquiredCMVat amedian
of 49 days (IQR 41-60) posttransplantation. CMV disease before day 100 occurred in 6 of 447 (1.3%) patients
and in 7 of 447 (1.6%) after day 100. The donor graft, specifically the total nucleated cell count (adjusted
hazard ratio [HR] 2.7; 95% confidence interval [CI], 1.4-4.7, P 5 .0002), was the only factor associated
with CMV transmission in multivariable analyses. Notably, the source stem cells (marrow versus peripheral
blood stem cell [PBSC]), screening method, and graft-versus-host disease (GVHD) were not associated with
transmission. Thus, a highly cellular graft was the only identifiable risk factor associated with CMV transmis-
sion, suggesting that viral genomic content of the donor graft determines transmission efficiency in D1/R2
HCTrecipients.
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The b herpesvirus cytomegalovirus (CMV) is the
most frequent viral complication following hemato-
poietic cell transplantation (HCT). CMV seropositive
recipients (R1) have consistently been shown to be at
highest risk for developing CMV infection and disease
in HCT [1]. Seronegative patients who receive sero-
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6/j.bbmt.2012.02.008CMV transmission, and prior studies suggest that ap-
proximately 9% to 21% will develop CMV posttrans-
plantation [2-6]. D1/R2 recipients have also been
shown to have a higher incidence of non-CMV in-
fections and an overall mortality disadvantage when
compared with seronegative recipients who receive
seropositive grafts (D-/R-) [2].
With improvements in strategies to prevent
transfusion-associated CMV [7-9], the seropositive
allograft is likely responsible for most if not all
CMV transmission during the first 100 days after
transplantation in D1/R2HCT recipients. Not only
are specific cellular reservoirs for CMV latency in
donor grafts still debated [10], but donor and recipient
factors associated with CMV transmission during
transplantation are also poorly understood [1]. In
order to better understand primary CMV, we set out
to determine risk factors associated with CMV trans-
mission in a large single-center cohort of D1/R2
HCT recipients. Our primary goal was to assess the
association between CMV transmission in D1/R2
transplantations and the cellular components of the
seropositive donor graft. Additionally, we assessed
other pre- and posttransplantation factors thought to
potentially alter risk for CMV transmission in this
population.1391
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Subjects
We evaluated a cohort of CMV seronegative HCT
recipients who underwent their first allogeneic HCT
from a seropositive donor at the Fred Hutchinson
Cancer Research Center (FHCRC) in Seattle, WA,
between January 1, 1995, and December 31, 2007.
Subjects who had been tested weekly for CMV, had
complete screening data, and survived long enough
to undergo center-based preemptive screening were
eligible for inclusion in this study. Patients were ex-
cluded if they either died before initiating standard
CMV testing (around day 10 after HCT) and did not
develop CMV disease, or if they had no record of
either antigenemia or polymerase chain reaction
(PCR) testing for CMV during their posttransplanta-
tion period. Subjects who had undergone tandem
transplant but were receiving their first allogeneic
transplant were eligible for inclusion in this cohort.
All study activities were approved by the FHCRC
institutional review board, and all participants pro-
vided written informed consent according the princi-
ples of the Declaration of Helsinki.
Data Source
Retrospective data were retrieved from a prospec-
tively collected database of patients undergoing HCT
at the FHCRC. In this dataset, pre- and posttransplan-
tation demographic and outcome data were available
for the first 100 days after HCT from clinical databases
and medical records. Clinical and laboratory records
after discharge are maintained in a long-term follow-
up database and were also available for review.
Transplant Standards, Viral Prevention, and
Surveillance
All patients and were followed using a preemptive
strategy for CMV prevention. Testing consisted of
either the pp65 antigenemia assay and or dual primer
PCR testing of the plasma [11-13]. Subjects tested
for antigenemia underwent weekly monitoring
beginning around day 20, when sufficient neutrophil
counts were present to allow for testing. Subjects
tested by PCR underwent weekly testing of plasma
for CMV DNA beginning the first week after
transplant. All patients were tested until day 100
after HCT for primary CMV infection [14].
The institutional cutoff for initiation of preemptive
antiviral therapy during the first 100 days after HCT
was antigenemia at any level or any PCR level .500
copies/mL, unless patients were receiving .1 mg/kg
of steroids at the time of diagnosis or had undergone
a T cell–depleted transplantation procedure, where
the cutoff was set at .100 copies/mL. Upon detection
of CMV infection, patients were started on induction-dose ganciclovir or foscarnet followed by maintenance
therapy [15]. ‘‘Noninterpretable’’ or an insufficient
number of cells for antigenemia results were not
treated, but patients were retested approximately 2 to
4 days later. All patients received seronegative or
leukoreducedbloodproductsper institutionalprotocol.
Antigenemia testing was the primary screening
method for preemptive therapy from 1995 through
2005, at which point CMV PCR testing became rou-
tinely available. During the period between 2005 and
February 2007, the use of PCR testing was driven by
the discretion of the primary attending physician and
someprimary oncologyprotocols; PCR testing became
the primarymethod beginning inFebruary 2007. In or-
der to assess the diagnostic effect of PCR testing, a sub-
set of patients who were tested initially by antigenemia
methods and who had stored frozen plasma available
were retested by PCR methods. These samples, which
had been frozen at 220C at the time of collection,
were thawed and retested for CMVDNA using a stan-
dardized dual-primer PCR-based assay [12].
All subjects received low-dose acyclovir or valacy-
clovir prophylaxis for herpes simplex virus 1 and 2 and
varicella-zoster virus as has previously been described
[16], but none received high-dose acyclovir. All
subjects receiveddaily fluconazole as antifungal prophy-
laxis and standard Pneumocystis jirovercii antimicrobial
therapy after engraftment. Patients who were neutro-
penic received prophylactic antibacterial therapy. Pa-
tients in our system have baseline IgG levels and then
are tested routinely at 130, 160, and 190 posttrans-
plantation. Patients with IgG levels\400 receive 400
mg/kg/month with postinfusion trough levels obtained
monthly and redosed if levels remain low.Conditioning
for HCT, as well as prophylaxis and treatment of graft-
versus-host disease (GVHD), were performed accord-
ing to current protocols standardized within the center
as previously described elsewhere [15].
Definitions
For the purposes of this study, seronegative recip-
ients who received a seropositive graft and developed
any detectable CMV during the posttransplantation
period were considered to have developed primary
‘‘CMV transmission.’’ Transmission detected in blood
was defined as detection of any antigenemia or detec-
tion of CMV DNA by PCR in the plasma. As has
been previously described, patients who developed
CMV detectable by PCR but who cleared their
DNAemia without therapeutic intervention or the de-
velopment of disease were considered to have abortive
infections [17]. CMV disease was defined by standard-
ized criteria [18].
Subjects were followed to day 1100 for the devel-
opment of any CMV in blood and until 365 days after
transplantation if they developed evidence of CMV
transmission in the first 100 days; all were followed
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purposes of analysis, patients were classified by the
screening method used posttransplantation (antigene-
mia only versus PCR only), except patients who under-
went a mix of testing strategies or had retrospective
PCR testing, who were classified as combination anti-
genemia/PCR. Fungal infections were defined by stan-
dard criteria [19] and patients with 1 or more positive
blood cultures for Gram negative (GNR) bacteria dur-
ing the first 100 days were considered to have GNR
bacteremia. Acute GVHD (aGVHD) and chronic
GVHD were defined according to established criteria
[20] and subjects were divided into low and high-risk
groups based on their primary malignancy at trans-
plantation [21].
Statistical Analysis
Probabilities of CMV transmission were summa-
rized using cumulative incidence estimates [22], where
death or retransplantation were considered competing
risks. To assess the utility of different preemptive
screening methods, a subanalysis of all patients who
had both antigenemia and PCR testing was completed,
and cumulative incidence curves were used to summa-
rize the rates ofCMVacquisition detected.Univariable
Cox proportional hazard regression models were used
to examine the effect of host-, donor-, and transplant-
associated factors on the development of CMV trans-
mission at any site posttransplantation in CMV D1/
R2HCT recipients. The following demographic vari-
ables were assessed: recipient and donor age, race, sex,
stem cell source, underlying disease risk, conditioning
regimen, and GVHD prophylaxis. The development
of aGVHD (grade 0-2 versus 3-4) was evaluated in
the model as a time-dependent risk factor. Addition-
ally, hematologic and graft-associated risk factors
were included: cellular components of the graft
(CD14,CD34, total nucleated cells [TNC], andmono-
nuclear cell count), donor and recipient ABOtypes, and
number of platelet and red blood cell (RBC) units
transfused. Because of the large variance in values for
graft components and number of platelet and RBC
units, these continuous variables were categorized in
quartiles for the purposes of analyses.
A multivariable Cox proportional hazards model
was built using a priori factors drawn from prior stud-
ies, including donor age, number of RBC units, and
aGVHD. Other factors associated with CMV in uni-
variable analyses (P\ .20) were also included in mul-
tivariable analyses. Because CD34, TNC, and graft
cell type are not independent variables, quartiles of
CD34 were assessed in multivariate analysis in place
of TNC to determine the hazard ratios specifically as-
sociated with this variable; graft cell type was not in-
cluded in multivariate models. A receiver-operating
curve was used to determine a specific threshold for
TNC of the graft and CMV acquisition.Additional assessment of risk of bacterial and
fungal infections related to development of CMV
transmission was assessed in a Cox proportional multi-
variable model that included age (.40 or #40), HLA
mismatching, unrelated donor status, myeloablative
versus nonmyeloablative transplant, CMV detected
in blood, and aGVHD (grade 2-4). Patients with pre-
existing fungal infections were excluded from analyses
of fungal incidence. CMV transmission and GVHD
were considered time-dependent variables in these
analyses. Finally, overall mortality and nonrelapse
mortality were assessed in a Cox proportional multi-
variate model, which included disease risk and any
CMV detection and GVHD (grade 3-4) as time-
dependent variables. All statistical analyses were per-
formed using SAS 9.1 (SAS Institute Inc., Cary, NC).RESULTS
Study Population
From January 1995 to December 2007, 471 pa-
tients underwent a CMV D1/R2 allogeneic trans-
plant procedure at the FHCRC in Seattle, WA. Of
these eligible patients, 24 were excluded because they
died before the institution of CMV testing or they
had incomplete CMV screening data, leaving 447 pa-
tients eligible for inclusion in this cohort. Patient de-
mographic and transplant characteristics are shown in
Table 1. The majority of patients underwent HCT
for leukemia (acute myelogenous leukemia, acute lym-
phoblastic leukemia, and chronic myeloid leukemia)
and received non-T cell–depleted myeloablative con-
ditioning; only a small portion received antithymocyte
globulin during conditioning (27 of 477 [5.7%]). More
than one-half had primary malignancies that were con-
sidered to be high risk at time of transplantation.
All patients underwent surveillance for CMV post-
transplantation during the first 100 days (Figure 1).
The majority of patients underwent testing by antige-
nemia only (393 of 447 [88%], compared with antige-
nemia/PCR (28 of 447 [6%]) and PCR only (26 of 447
[6%]). A total of 65 (14.5%) patients underwent addi-
tional testing by CMV PCR on stored frozen samples.
A subset of those were tested initially by antigenemia
only (n 5 49), whereas the others had a mix of antige-
nemia/PCR (n 5 16) during the immediate posttrans-
plantation period. All patients in this subset had repeat
PCR testing on their stored blood. Patients who had
retrospective testing by PCR were included in the
PCR group for purposes of analyses.
CMVOutcome
CMV acquisition
CMV transmissionwas detected in 85 of 447 (19%)
patients during the first year posttransplantation.
Table 1. Population Demographic Characteristics (n 5 447)
Characteristics n (%)*
Age
Median (IQR) 42.3 (31.2-51.6)
Sex
Male 286 (64)
Female 161 (36)
Race/Ethnicity
Caucasian 356 (80)
Hispanic 21 (5)
Asian Pacific-Islander 18 (4)
Native American 12 (3)
African American 9 (2)
Other 31 (7)
Disease
AML 133 (30)
CML 93 (21)
MDS 68 (15)
ALL 65 (15)
NHL 29 (6)
MM 19 (4)
HD 12 (3)
Other 28 (6)
Risk category†
High 238 (53)
Low 209 (47)
Graft
Bone marrow 218 (49)
PBSC 229 (51)
Donor relationship
Sibling 222 (50)
Unrelated 194 (43)
Haploidentical 27 (6)
Other 4 (<1)
HLA disparity
Matched 326 (73)
Mismatched 121 (27)
ABO disparity
Matched 223 (50)
Mismatched 224 (50)
Conditioning regimen
Myeloablative
CY/TBI 172 (38)
BU/CY 126 (28)
T cell–depleted 27 (6)
Other 42 (9)
Nonmyeloablative
Flu/TBI 54 (12)
Other 26 (6)
GVHD prophylaxis
CSP/FK-506 ± MTX 325 (73)
MMF 94 (21)
Others 28 (6)
IQR indicates interquartile range; AML, acute myelogenous leukemia;
CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome;
ALL, acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma; MM,
multiple myeloma; HD, Hodgkin’s lymphoma; PBSC, peripheral blood
stem cell; HLA, human leukocyte antigen; CY, cytoxan; TBI, total body
irradiation; BU, busulfan; Flu, fludarabine; CSP, cyclosporine; MTX,
methotrexate; MMF, mycophenolate mofetil.
*Data are no. (%) of patients, unless otherwise indicated. Values may not
equal 100% because of rounding.
†High risk: accelerated phase, blast crisis, or relapse; low risk: remission
or chronic phase.
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detected before day 100 (Figure 2), and an addi-
tional 9 of 447 (2%) had CMV transmission detected
between day 100 and 1 year. Themedian time to devel-
opment of CMV transmission in the first year post-transplantation was 49 days (interquartile ratio [IQR]
41-60).
CMV detection in blood
A total of 81 of 447 (18.1%) patients had evidence
of CMV transmission detected in blood through a pos-
itive antigenemia or plasma PCR during the first year
posttransplantation. The majority (73 of 447 [16.3%])
of patients were positive during the first 100 days, the
period of routine preemptive screening; 8 of 447 (2%)
were positive beyond 100 days. The overall incidence
of CMV in the first year posttransplantation was
higher in subjects tested by PCR during the preemp-
tive period (25 of 103 [24.3%]) than in those tested
by antigenemia only (56 of 344 [16.3%]) (P 5 .065).
Because a small number of patients were tested by
PCR only (6 of 26 [23%]), and because rates were com-
parable to those tested by a combination of antigene-
mia/PCR (29 of 77 [25%], P 5 .87), these 2 groups
were combined for the purposes of analyses.
The median level of first detection in patients who
were antigenemia positive by day 100 was 2 cells/slide
(IQR 1,6), and the median maximum detected level
was 6 cells/slide (IQR 1,18). The median level of first
detection in patients who were PCR positive by day
100 was 64 copies/mL (IQR 44, 315), and the median
of the maximum viral load detected was 1467 copies/
mL (IQR 167, 7401). Patients who were tested by
PCR at some point within the first 100 days had CMV
detected earlier posttransplantation (median 41 days,
IQR 31, 56) when compared with those tested by anti-
genemia only (median 49.5, IQR 45, 55) (P5 .02).
A total of 49 patients who were initially tested by
antigenemia only and 16 patients in the antigenemia/
PCR only group underwent retrospective PCR testing
to supplement data and to assure testing for the entire
posttransplantation period for bothmodalities (n5 65)
(Figure 1). Of this subgroup, 11 of 65 were positive by
antigenemia (17%) and 13 of 65 by PCR (20%)
(Figure 3A). Nine patients were positive by both
methods: 2 only by antigenemia and 4 only by PCR
testing. Of the 9 total patients detected by both
methods, 7 of 9 (80%) were found earlier by PCR at
a mean of 10.6 days earlier (range: 7-15) than by anti-
genemia and all had a low viral load detected (mean
53 copies/mL [range: 43-421]); 2 patients were positive
by PCR and antigenemia on the same day.
CMV disease
A total of 6 of 447 (1.3%) patients developed CMV
disease during the first 100 days posttransplantation at
amean of 50.3 days (range: 19-78). Site ofCMVdisease
included 3 gastrointestinal (GI) disease, 1 pneumonia,
and 1 each with disseminated disease and biopsy-
proven invasive sinus disease. A similar percentage pre-
sented with disease (7 of 337 [1.5%]) from day 101 to 1
year posttransplantation. Pneumonia was the most
AG & PCR 
combination
n = 28
n = 49
AG only
n = 344
AG/PCR
n = 77
PCR only
n = 26
PCR-based
n = 26
AG-based
n = 393
Any AG
Any AG or 
Pre-specified 
PCR levels†
Pre-specified 
PCR levels*
Initial Posttransplantation 
Screening Approach
Study Subsets
Preemptive Treatment 
Levels
n = 16
Additional Late 
PCR Testing
n = 65
Figure 1. Schema of CMV screening and development of study subsets
(n 5 447). Abbreviations: AG, antigenemia; PCR, polymerase chain re-
action; † treated for any AG, except a few cases that had both AG testing
and PCR where patients were given preemptive therapy for positive
PCR at varying levels, *patients given preemptive therapy at CMV
PCR levels $500 copies/mL, except patients on $1 mg/kg of steroids
who are started on treatment at a level of $100 copies/mL.
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Figure 2. Cumulative incidence of CMV transmission by day 100 in
a cohort of CMV D1/R2 hematopoietic cell transplant recipients
(n 5 447). Abbreviations: CMV, cytomegalovirus; D1, donor positive;
R2, recipient negative. Patients censored at date or last contact, and
death and retransplantation were considered competing risks.
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in Seronegative HCT Recipientscommon cause of late disease (n 5 4), followed by GI
disease (n 5 3); late disease occurred at a mean of
150.3 days (range: 101-314). There was no difference
in rates of disease based on type of primary surveillance
in the immediate posttransplantation period (antigene-
mia/PCR 2 of 103 [1.9%] versus antigenemia only (4 of
344 [1.1%], P 5 .62) or the late period (antigenemia/
PCR 1 of 103 [0.97%] versus antigenemia only 6 of
344[1.7%]), P 5 .69); none of those tested by PCR
only developed disease. Three patients presented
with disease as their only manifestation of CMV trans-
mission:, 2 with early GI disease (days 19 and 47) and 1
with late pneumonia (day 314). One additional patient
developed invasive sinus disease, proven by histopa-
thology, before developing antigenemia (day 55 versus
71).
Abortive Infections
Because all patients who had any positive level of
antigenemia were given preemptive ganciclovir per in-
stitutional standard practice, only patients tested by
PCR could have potentially developed a level of detec-
tion belowwhich therapy was not administered. A total
of 4 of 102 (3.9%) patients tested by PCR were noted
to have CMV DNAemia detected but did not receive
antiviral therapy. Initial detectable CMV DNAemia
levels (mean 61.8 copies/mL [range: 27-140]), and
maximum values (mean 101.5 copies/mL [range: 39-
167]) were low. Two had more than 1 positive weekly
sample (2 and 4 weeks after the first), including a pa-
tient who had retrospective sampling on frozen sam-
ples. Of these 4 patients, all survived .3 months
posttransplantation, and by definition, no patient
with an abortive infection developed CMV disease or
required CMV therapy [17].
CMV shedding
Only 1 patient was noted to be positive by shed-
ding only; our center does not routinely assess forCMV shedding. This patient was found to have
CMV by culture from nasal wash at day 69 posttrans-
plant but did not develop other CMV related compli-
cations.RISK FACTOR ANALYSES
In univariable analyses, patients transplanted with
a higher number of TNC in their graft (upper fourth
quartile) were at significantly higher risk for CMV
transmission (hazard ratio [HR] 2.0; 95% confidence
interval [CI], 1.2-3.1) (Table 2). Additionally there
was a trend toward an association with a higher risk
for CMV transmission with a higher quartile of
CD34 cells in the graft (HR 1.5; 95% CI, 0.9-2.6).
Other cellular components, such as mononuclear cell
count and CD14 components of the graft, did not ap-
pear to alter risk of CMV acquisition.
The only other transplant factors that appeared to
potentially alter the risk for CMV transmission were
donor blood type B when compared with blood type
A and donor graft type (peripheral blood stem cell ver-
sus bone marrow). Other donor blood types (AB and
O) were similar to blood type A, and there was no as-
sociation with recipient blood type or blood type mis-
match (Table 2). The total number of RBC units
transfused (highest quartile) (HR 0.99; 95% CI 0.6-
1.7) and number of platelet transfusions (highest quar-
tile [HR 0.97; 95% CI 0.6-1.7]) were not associated.
All other potential risk factors were not associated
with CMV transmission, including the use of antithy-
mocyte globulin during conditioning (data not
shown).
Inmultivariable analyses, a highTNC in the donor
graft (HR 2.7; 95% CI, 1.4-4.7, P5 .0002) was signif-
icantly associated with CMV transmission. There were
trends toward increased rates of transmission detected
in those tested by antigenemia/PCR during follow-up
(HR 1.5; 95% CI, 0.9-2.5), and toward protection
from transmission by donor ABO type (others versus
PCR
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Figure 3. Cumulative incidence of CMV transmission detected in
blood by testing method* and total nucleated count in graft (in quartiles)
in a cohort of CMV D1/R2 hematopoietic cell transplant recipients
(n 5 447). (A) CMV outcomes by testing method. Abbreviations:
CMV, cytomegalovirus; D1, donor positive; R2, recipient negative; anti-
genemia 5 pp65 antigenemia testing; PCR, polymerase chain reaction
testing. Patients censored at date or last contact, and death and retrans-
plantation were considered competing risks. *This figure represents pa-
tients who had supplemental retrospective PCR testing to assure
complete testing by both modalities. (B) CMV incidence by total nucle-
ated count quartiles. Patients censored at date of last contact, and death
and retransplantation were considered competing risks.
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CD34 was replaced in the model for TNC, it demon-
strated a trend toward an association (HR 1.6; 95%CI,
0.9-2.9) that did not reach statistical significance. Cu-
mulative incidence curves for the quartiles of TNC are
also shown in Figure 3B. In order to assess if there was
a threshold for CMV transmission based on the TNC
of the graft, a receiver-operating curve was performed
(Figure 4). All other transplant and hematologic fac-
tors, including conditioning regimen, RBC units
transfused, donor age, andHLAmatching were not as-
sociated with CMV transmission inmultivariable anal-
yses.OTHER COMPLICATIONS
A total of 50 (11%) patients developed GNR infec-
tions during the first 100 days following transplanta-
tion, and 68 of 447 (15%, 50 invasive molds, 18
candidemia) developed fungal infections in the first
year posttransplantation. In univariable models, nei-
ther GNR bacteremia (HR 1.06, 95% CI 0.53-2.12)nor fungal infections (HR 1.00, 95% CI 0.46-2.14)
were associated with CMV infection in the blood in
this cohort. Multivariable analyses demonstrated no
association between CMV transmission detected in
blood and GNR bacteremia at day 100 (HR 0.90,
95% CI 0.10-8.40) or fungal infections at 1 year (HR
1.01, 95% CI 0.47-2.18). Detection of CMV was
also not associated with a risk of overall mortality
(HR 0.96, 95% CI 0.60-1.53) or nonrelapse mortality
at 1 year (HR 1.18, 95%CI 0.68-2.05) in multivariable
analyses.DISCUSSION
CMV seronegative HCT recipients who receive
a seropositive graft are at significant risk forCMVcom-
plications following hematopoietic cell transplantation.
In our cohort, 20% of D1/R2 patients developed
CMV transmission during the first year of follow-up,
and 3%developed invasive disease. The only risk factor
associated with CMV transmission was a high graft
TNC count. Other cellular components of the donor
graft, including monocytes (CD14), did not appear to
affect CMV transmission. No other pre- or posttrans-
plant risk factors appeared to alter efficiency of CMV
transmission, although the addition of CMVPCR test-
ing did appear to detect CMV transmission earlier and
identified several abortive infections.
Epidemiologic data have demonstrated that CMV
seropositive recipients are at highest risk for the
development of CMV complications. The majority of
epidemiologic and intervention trials focus on this
high risk population or combine D1/R2 with R1
patients. Even studies focusing on risk related to donor
CMVserostatushave centeredonseropositive recipients
[23,24]. This distinction is important because CMV
outcomes seen in seropositive recipients are because of
different pathologic mechanisms than those that occur
in D1/R2 transplant recipients. In seropositive
recipients, CMV complications primarily stem from
reactivation of latent virus [25,26], whereas in
seronegative patients these events indicate transmission
of virus. Risk factors for development of CMV in D1/
R2 patients may therefore be very different than those
seen in seropositive recipients, depending less on
posttransplant immunosuppression and more on total
exposure to the virus [27]. Furthermore, there are no
studies that have focused on the smaller population of
D1/R2 patients and assessed risk factors for CMV ac-
quisition that are specific to this population.
These data help to define the importance of the
donor graft as the most frequent source of CMV
transmission in D1/R2 recipients. Previous studies
have suggested that in infected individuals, bone
marrow-derived hematopoietic cells, granulocyte-
macrophage progenitors, and peripheral blood
Table 2. Cox Regression of Risk Factors for Any CMV
Transmission (n 5 77) during the First 100 Days after Trans-
plantation in D+/R2 Patients (n 5 447)
Risk Factor
Univariable HR
(95% CI)
Multivariable†
HR (95% CI) P Value
Demographic factors
Recipient age (per 10 years) 1.0 (0.9-1.2) —
Donor age (per 10 years) 0.9 (0.8-1.1) 0.9 (0.7-1.1) .15
Gender
Recipient
Male 1 —
Female 1.2 (0.8-2.0)
Donor
Male 1 —
Female 1.0 (0.6-1.6)
Risk group
High 1 —
Low 1.0 (0.7-1.6)
Transplant characteristics
Conditioning regimen
Myeloablative 1 1 .26
Nonmyeloablative 1.6 (0.9-2.6) 1.4 (0.8-2.6)
GVHD prophylaxis
CSP/FK-506 ± MTX 1
MMF 1.4 (0.9-2.4) —
Others 0.7 (0.2-2.3)
aGVHD
Grade 0-2 1 —
Grade 3-4 0.7 (0.2-2.8)
CMV test method
AG only 1 1 .12
PCR or AG + PCR 1.7 (1.1-2.8) 1.5 (0.9-2.5)
Graft characteristics
Cell type
BM 1 —
PBSC 1.7 (1.1-2.7)
HLA matching
Matched 1 1
Mismatched 1.2 (0.6-2.6) 1.9 (0.9-4.3) .11
Unrelated 0.7 (0.4-1.1) 1.2 (0.7-2.2) .54
ABO recipient
A 1
B 0.8 (0.4-1.9) —
AB 1.1 (0.7-1.8)
O NA
Donor 1
A 1
B 0.2 (0.05-0.9) 0.3 (0.1-1.1) .06
AB 1.1 (0.7-1.8) 1.0 (0.6-1.8) .83
O 1.1 (0.3-3.4) 1.5 (0.4-5.1) .51
ABO mismatch
Matched 1 —
Mismatched 0.9 (0.6-1.4)
Cellular components
TNC‡
Below Q3 1 1
Above Q3 2.0 (1.2-3.1) 2.7 (1.6-4.7) .0002
CD-14
Below Q3 1 —
Above Q3 0.9 (0.5-1.8)
MNC
Below Q3 1 —
Above Q3 1.0 (0.5-2.3)
Transfusion risks
Total RBC units 1
Below Q3 1 0.7 (0.4-1.3) .25
Above Q3 0.99 (0.6-1.7)
Total PLTunits —
Below Q3 1
Above Q3 0.97 (0.6-1.7)
D+/R2 indicates donor positive/recipient negative; CSP, cyclosporine;
FK, FK-506 (tacrolimus); MMF, mycophenolate mofetil; AG, antigenemia;
BM, bone marrow; PBSC, peripheral blood stem cell; HLA, human leu-
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reactivation occurs during immunosuppression or
immunodeficiency [28-34]. These cells can support
active CMV replication and the allogeneic transplant
process itself may stimulate reactivation [35]. Still, the
challenge of successfully reactivating CMV from natu-
rally infected samples in the laboratory has limited the
ability to translate these findings into clinically relevant
predictors for transmission [27,35]. Although deter-
mining a cell-specific reservoir ofCMVlatencyhas con-
tinued to be a source of ongoing research [10,35], the
lack of such models has hampered the development of
prevention strategies in this population.
Donor PBSC as a graft source was also associated
with CMV transmission in univariable analyses and is
consistent with data from a recent randomized trial
that demonstrated a trend toward higher rates of
CMV complications in PBSC graft recipients [36].
The association did not remain statistically significant
in multivariable analyses, suggesting that the higher
cellular content found in PBSC grafts when compared
with bone marrow plays a more important role than
the type of graft [37-39]. We also analyzed other
pretransplant risk factors considered to be associated
with CMV transmission, including total-body irridia-
tion dose, donor age, HLA matching, as well as post-
transplant factors such as aGVHD [24,40-43]. In our
study, aGVHD itself, as well as other factors
associated with the development of GVHD such as
immunosuppressive prophylaxis [42,43], were not
associated with CMV transmission. HLA matching
and conditioning with TBI also had no clear
association with transmission. Similarly, although
previously reported in the context of blood
transfusion-associated CMV transmission [8], we
found no associations between transmission and num-
ber of RBC or platelet units transfused. Perhaps it is
the allogeneic process itself, as has been suggested,
that is the most important factor leading to the lytic
phase of replication and subsequent detection [35].
The close association with donor blood type B seen
in univariate analyses is unclear. There are no known
associations between ABO blood type and CMV, and
this association did not appear to be linked to ABO
mismatch between the donor and recipient. Risk of vi-
ral infections has been associated with ABO blood
type. Interestingly blood type B has been associated
with a decreased risk of Norovirus infection [44] butkocyte antigen; Q3, third quartile; MNC, mononuclear count; PLT,
platelets.
Because of rounding not all values equal 100.
†Multivariate model adjusted a priori risk factors and risk factors
associated with P < .20 in univariate analyses. Factors in multivariate
model included, donor age, HLA matching, CMV test method, TNC
of graft, donor ABO, and total RBC units transfused.
‡All results run with TNC, except CD-34, which replaced TNC in the
multivariate model for this result.
Figure 4. ROC analysis of total nucleated count and any CMV reacti-
vation.* Abbreviations: ROC, receiver-operating curve; CMV, cytomeg-
alovirus; AUC, area under the curve. *Any CMV reactivation includes
both patients with shedding and disease only. Best sensitivity (64%)
and specificity (59%) at TNC of 7.84  108.
1398 Biol Blood Marrow Transplant 18:1391-1400, 2012S. A. Pergam et al.an increased risk for HHV-8 infection [45]. Although
there continued to be a trend in multivariate analyses,
this association did not remain significant. Addition-
ally, the percentage of donors with blood type B
(10.5%) was consistent with those reported in multi-
center blood donor registry data, suggesting no base-
line protection from CMV infection [46]. Although
it is possible that donor blood type B is more resistant
to primary CMV infection, this needs further evalua-
tion in larger cohort studies.
CMV transmission was more frequently detected
and at earlier time points by PCR testing during the
posttransplant period than with standard antigenemia
testing; however, the effect of this improved detection
was not statistically significant when controlling for
other factors such as TNC. Also, in a subset of patients
who were tested by both methods, PCR identified
CMV transmission earlier than antigenemia but the
rates of detection were similar (Figure 3A). The risk
of CMV transmission in seronegative recipients in
prior studies is reported to be between 9% and 21%
[2-5,15,47], although population differences (eg,
pediatric versus adult) and variable prevention and
screening strategies make comparisons between
studies difficult. We found that approximately 19%
of patients acquired CMV during the first year
posttransplantation. Furthermore, the higher rates
seen in those tested by PCR indicate that rates of
CMV transmission in D1/R2 transplant recipients
may actually be higher than previously reported.
However, some of those detected by PCR are likely
abortive infections [17]. The cases of abortive infection
described in this study are plausible because viral load
was low and patients did not progress to antigenemia
or disease. Earlier detection through PCR screening
did not appear to translate into lower CMV disease
rates. This is not surprising, considering that there
were only a small number of patients who were missed
by antigenemia and relatively few that developed
preengraftment CMV, a time period where PCR has
advantages over antigenemia. Finally, CMV transmis-sion was not associated with bacterial or fungal com-
plications.
The strengths of our study include the size of our
cohort, the uniformity of prevention strategies, and
consistency of short and long-term clinical data avail-
able for review. As with all retrospective studies, these
analyses are not without limitations. We included all
patients with evidence of CMV infection from plasma
or disease locations, but it is possible that we missed
evidence of transmission through viral shedding at
other sites. Urine and oral screening may have little
relevance for disease outcomes [48-50], suggesting
that additional screening from nonblood sites would
not have altered our results. Although not all patients
were tested with both PCR and the antigenemia
assay, we do not think that this affected that
transmission rate significantly as both multivariate
model and the head-to-head comparison of PCR ver-
sus antigenemia did not suggest a statistically signifi-
cant increase in detecting CMV transmission
(although PCR detected it earlier).
Although it is possible that seropositive recipients
who were falsely seronegative on screening may have
been included in our cohort, it is unlikely to have af-
fected our results because misclassification of serosta-
tus is a very uncommon event. Although we did not
find an association with blood transfusions, the most
likely alternate source during transplantation, we
could not account for other possible sources of CMV
acquisition not included in our risk factor analyses.
The amount of intravenous immunoglobulin use is
not available in this dataset and may have affected rates
of CMV transmission in this cohort; however, the
modest benefit seen with weekly CMV-specific
intravenous immunoglobulin [51] suggests that this
would have had little impact on these analyses. Finally,
the limited data on the specific cellular makeup of the
seropositive graft and T cell reconstitution following
transplantation do not allow for a complete in-depth
analyses of other graft components and immune re-
constitution on CMV outcomes.
In summary, we demonstrate a critical role for the
cellularity of the donor graft in CMV transmission in
D1/R2 HCT recipients. Our improved preemptive
strategies have helped to decrease the rate of CMV dis-
ease in HCT [52], but it remains an important yet elu-
sive goal to prevent primary transmission in the D1/
R2 population. These data make a strong case for the
importance of the donor graft in primary CMV trans-
mission to D1/R2 patients, but suggest that until we
understand primaryCMVbiology theremay be limita-
tions in our ability to intervene to prevent CMV trans-
mission. As such, future studies aimed at understanding
primary reservoirs for latent CMV within the donor
graft and the role of viral load in transmission are
needed. Assessments of transplant or immunologic fac-
tors, such as the role of concomitant transfer of donor-
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in Seronegative HCT Recipientsderived cellular and humoral immunity associated with
conversion from latent to lytic replication, are also
needed. Future studies addressing recipient target cell
receptors and host genetics, or those evaluating donor
immunity may provide additional predictors for viral
transmission that could lead to important changes in
donor selection or assist in risk stratification.ACKNOWLEDGMENTS
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